Xenothera is a xenotherapy platform utilizing a glyco humanized antibody technology to enhance immunological treatments for various diseases. The platform aims to improve patient outcomes by providing more effective therapeutic options in clinical trials, including treatments for pancreatic cancer and peripheral T-cell lymphoma.
Funding
$21.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current immunological treatments often fall short in effectively targeting and neutralizing disease-causing agents, leading to suboptimal patient outcomes. Traditional antibody therapies may lack the necessary specificity and efficacy to combat complex diseases like cancer and lymphoma.
Solution
Xenothera is developing a xenotherapy platform that leverages glyco-humanized antibody technology to create enhanced immunological treatments. By modifying the glycosylation patterns of antibodies, Xenothera aims to improve their ability to stimulate the immune system and target specific disease markers. This approach allows for the development of more effective therapeutic options, potentially leading to improved outcomes for patients with various diseases, including pancreatic cancer and peripheral T-cell lymphoma. The platform focuses on generating antibodies with enhanced immunological properties, offering a novel approach to immunotherapy.
Target Audience
The primary target audience includes patients with cancer and other immunological disorders, as well as clinicians and researchers seeking more effective therapeutic options.
Features
- Glyco-humanization technology to modify antibody glycosylation for enhanced immune response
- Development of XON11, a novel treatment for pancreatic cancer
- PALT1 trial for peripheral T-cell lymphoma (PTCL) with Orphan Drug Designation (ODD) by the EMA
- XAV-19, an anti-COVID antibody with demonstrated clinical efficacy
- Focus on research and development of innovative immunological treatments
- Utilization of molecular genetics, microbial physiology, immunology, cellular biology, and structural biology
- Preclinical and clinical trials to evaluate the safety and efficacy of novel antibody therapies